Scientists at Yale University have discovered a new treatment through a study of the pathogenesis of type 2 diabetes,media reported. The breakthrough focused on new understandings of how fasting can trigger the onset of type 2 diabetes, leading researchers to discover a way to intervene and cut off the process.
The team found that during fasting, two proteins — TET3 and HNF4a — accumulate in the liver and increase blood sugar. For healthy people, the process is cut off when the body exits fasting mode, but for people with type 2 diabetes, the cut-off leaves excess glucose and builds up in the blood.
In response, scientists came up with another way to shut it down to stop the disease. The team packed a genetic material called small molecule interference RNA , or siRNA, into a virus that targets TET3 or HNF4 and injected it into mice. As a result, they found that the technique could effectively lower protein and blood sugar levels, effectively preventing the development of diabetes.
In the second study, the team explored the role of TET3 in liver fibrosis. It is reported that liver fibrosis is a kind of healthy liver tissue scar, can lead to life-threatening diseases such as cirrhosis. They found that TET3 plays a role at three different points in the fibrosis signaling pathway, meaning that drugs for key proteins in type 2 diabetes can also be used to treat fibrosis, and that there are very limited drug options for treating fibrosis.